Intellia Therapeutics
A leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. Learn more
Launch date
Employees
Market cap
€2.0b
Enterprise valuation
€1.5b (Public information from Sep 2024)
Share price
$22.93 NTLA
Cambridge Massachusetts (HQ)
Authorizing premium user...